Biomimetic Theranostic Agents with Superior NIR-II Photoacoustic and Magnetic Resonance Imaging Performance for Targeted Photothermal Therapy of Prostate Cancer
Pharmaceutics · 30.05.2023 · 15 (6) · 1617
DOI: 10.3390/pharmaceutics15061617 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.05.2023. Verfasst von Ling Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, CAS Key Laboratory of Health Informatics, Guangdong Basic and Applied Basic Research Fund.
Abstract (Originalsprache)
The accurate diagnosis and treatment of prostate cancer at an early stage is crucial to reduce mortality rates. However, the limited availability of theranostic agents with active tumor-targeting abilities hinders imaging sensitivity and therapeutic efficiency. To address this challenge, we have developed biomimetic cell membrane-modified Fe2O3 nanoclusters implanted in polypyrrole (CM-LFPP), achieving photoacoustic/magnetic resonance dual-modal imaging-guided photothermal therapy of prostate cancer. The CM-LFPP exhibits strong absorption in the second near-infrared window (NIR-II, 1000–1700 nm), showing high photothermal conversion efficiency of up to 78.7% under 1064 nm laser irradiation, excellent photoacoustic imaging capabilities, and good magnetic resonance imaging ability with a T2 relaxivity of up to 48.7 s−1 mM−1. Furthermore, the lipid encapsulation and biomimetic cell membrane modification enable CM-LFPP to actively target tumors, leading to a high signal-to-background ratio of ~30.2 for NIR-II photoacoustic imaging. Moreover, the biocompatible CM-LFPP enables low-dose (0.6 W cm−2) photothermal therapy of tumors under 1064 nm laser irradiation. This technology offers a promising theranostic agent with remarkable photothermal conversion efficiency in the NIR-II window, providing highly sensitive photoacoustic/magnetic resonance imaging-guided prostate cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China.
- Paul C. Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
- Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Ch…
- Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430074, China.
Förderung
- National Natural Science Foundation of China
- CAS Key Laboratory of Health Informatics
- Guangdong Basic and Applied Basic Research Fund
- Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province
- the Science and Technology Key Project of Shenzhen
- Natural Science Foundation of China
Zitieren
APA
Liu, L., Yang, S., Zheng, Z., Li, Q., Liu, C., Hu, D., Liu, Z., Zhang, X., Zhang, R., & Gao, D. (2023). Biomimetic Theranostic Agents with Superior NIR-II Photoacoustic and Magnetic Resonance Imaging Performance for Targeted Photothermal Therapy of Prostate Cancer. Pharmaceutics, 15(6), 1617. https://doi.org/10.3390/pharmaceutics15061617
Vancouver
Liu L, Yang S, Zheng Z, Li Q, Liu C, Hu D, et al. Biomimetic Theranostic Agents with Superior NIR-II Photoacoustic and Magnetic Resonance Imaging Performance for Targeted Photothermal Therapy of Prostate Cancer. Pharmaceutics. 2023;15(6):1617. doi:10.3390/pharmaceutics15061617
BibTeX
@article{Liu2023,
author = {Liu, Ling and Yang, Shangpo and Zheng, Ziliang and Li, Qingshuang and Liu, Chenchen and Hu, Dehong and Liu, Zhou and Zhang, Xiaoping and Zhang, Ruiping and Gao, Duyang},
title = {Biomimetic Theranostic Agents with Superior NIR-II Photoacoustic and Magnetic Resonance Imaging Performance for Targeted Photothermal Therapy of Prostate Cancer},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {6},
pages = {1617},
doi = {10.3390/pharmaceutics15061617}
}
EUVIMED